Long term disease free survival in advanced melanomas treated with nitrosoureas: Mechanisms and new perspectives

Abstract

Background. Median survival of metastatic malignant melanoma is 6.0 to 7.5 months, with a 5-year survival of ∼ 6.0%. Although long-term complete remissions are rare, few reports describe cases after chemotherapy. Fifty-three patients with metastatic melanoma were treated with Cystemustine, a chloroethyl nitrosourea (CENU) (60 or 90 mg/m2). Case presentation. We describe 5 cases, presenting with complete response with long-term disease-free survival of long-term remission of 14, 12, 9, 7 and 6 years after Cystemustine therapy alone. Conclusion. Long-term survival has already been described in literature, but in all cases they have been obtained after chemotherapy associated with or followed by surgery. But despite these noteworthy and encouraging but also rare results, it appears essential to increase cystemustine efficiency. © 2005 Durando et al., licensee BioMed Central Ltd.